Jessica H Plager1, Christian M Mancini2, Xiaoqing Fu2, Serguei Melnitchouk3, Erica S Shenoy4, Aleena Banerji5, Laura Collier6, Nivedita Chaudhary7, Sharmitha Yerneni8, Yuqing Zhang9, Kimberly G Blumenthal10. 1. Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. 2. Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts; Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts; The Mongan Institute, Massachusetts General Hospital, Boston, Massachusetts. 3. Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. 4. Harvard Medical School, Boston, Massachusetts; Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts; Infection Control Unit, Massachusetts General Hospital, Boston, Massachusetts. 5. Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. 6. Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts. 7. Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. 8. Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital, Boston, Massachusetts. 9. Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts; The Mongan Institute, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. 10. Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts; Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts; The Mongan Institute, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. Electronic address: kblumenthal@mgh.harvard.edu.
Abstract
BACKGROUND: Cefazolin is a first-line prophylactic antibiotic used to prevent surgical site infections (SSIs) in cardiac surgery. Patients with a history of penicillin allergy often receive less effective second-line antibiotics, which is associated with an increased SSI risk. OBJECTIVE: To describe the impact of preoperative penicillin allergy evaluation on perioperative cefazolin use in patients undergoing cardiac surgery. METHODS: We performed a retrospective cohort study of patients with a documented penicillin allergy who underwent cardiac surgery at the Massachusetts General Hospital from September 2015 to December 2018. We describe penicillin allergy evaluation assessment and outcomes. We evaluated the association between preoperative penicillin allergy evaluation and first-line perioperative antibiotic use using a multivariable logistic regression model. RESULTS: Of 3802 cardiac surgical patients, 510 (13%) had a documented penicillin allergy; 165 (33%) were referred to allergy and immunology practitioners. Of 160 patients (31%) who underwent penicillin allergy evaluation (ie, penicillin skin testing and, if results were negative, an amoxicillin challenge), 154 (97%) were found not to have a penicillin allergy. Patients who underwent preoperative penicillin allergy evaluation were more likely to receive the first-line perioperative antibiotic (92% vs 38%, P < .001). After adjusting for potential confounders, patients who underwent preoperative penicillin allergy evaluation had higher odds of first-line perioperative antibiotic use (adjusted odds ratio, 26.6; 95% CI, 12.8-55.2). CONCLUSION: Integrating penicillin allergy evaluation into routine preoperative care ensured that almost all evaluated patients undergoing cardiac surgery received first-line antibiotic prophylaxis, a critical component of SSI risk reduction. Further efforts are needed to increase access to preoperative allergy evaluation.
BACKGROUND:Cefazolin is a first-line prophylactic antibiotic used to prevent surgical site infections (SSIs) in cardiac surgery. Patients with a history of penicillinallergy often receive less effective second-line antibiotics, which is associated with an increased SSI risk. OBJECTIVE: To describe the impact of preoperative penicillinallergy evaluation on perioperative cefazolin use in patients undergoing cardiac surgery. METHODS: We performed a retrospective cohort study of patients with a documented penicillinallergy who underwent cardiac surgery at the Massachusetts General Hospital from September 2015 to December 2018. We describe penicillinallergy evaluation assessment and outcomes. We evaluated the association between preoperative penicillinallergy evaluation and first-line perioperative antibiotic use using a multivariable logistic regression model. RESULTS: Of 3802 cardiac surgical patients, 510 (13%) had a documented penicillinallergy; 165 (33%) were referred to allergy and immunology practitioners. Of 160 patients (31%) who underwent penicillinallergy evaluation (ie, penicillin skin testing and, if results were negative, an amoxicillin challenge), 154 (97%) were found not to have a penicillinallergy. Patients who underwent preoperative penicillinallergy evaluation were more likely to receive the first-line perioperative antibiotic (92% vs 38%, P < .001). After adjusting for potential confounders, patients who underwent preoperative penicillinallergy evaluation had higher odds of first-line perioperative antibiotic use (adjusted odds ratio, 26.6; 95% CI, 12.8-55.2). CONCLUSION: Integrating penicillinallergy evaluation into routine preoperative care ensured that almost all evaluated patients undergoing cardiac surgery received first-line antibiotic prophylaxis, a critical component of SSI risk reduction. Further efforts are needed to increase access to preoperative allergy evaluation.
Authors: Ryan P Merkow; Mila H Ju; Jeanette W Chung; Bruce L Hall; Mark E Cohen; Mark V Williams; Thomas C Tsai; Clifford Y Ko; Karl Y Bilimoria Journal: JAMA Date: 2015-02-03 Impact factor: 56.272
Authors: Kimberly G Blumenthal; Erin E Ryan; Yu Li; Hang Lee; James L Kuhlen; Erica S Shenoy Journal: Clin Infect Dis Date: 2018-01-18 Impact factor: 9.079
Authors: Kimberly G Blumenthal; Emily M Huebner; Xiaoqing Fu; Yu Li; Gita Bhattacharya; Amy S Levin; Christian M Mancini; Benjamin R Slawski; Aleena Banerji Journal: J Allergy Clin Immunol Pract Date: 2019-04-11
Authors: Deanna L McDanel; Antoine E Azar; Amy M Dowden; Samantha Murray-Bainer; Nicolas O Noiseux; Melissa Willenborg; Charles R Clark; John J Callaghan; Ambar Haleem Journal: J Arthroplasty Date: 2017-01-17 Impact factor: 4.757
Authors: Sandra I Berríos-Torres; Craig A Umscheid; Dale W Bratzler; Brian Leas; Erin C Stone; Rachel R Kelz; Caroline E Reinke; Sherry Morgan; Joseph S Solomkin; John E Mazuski; E Patchen Dellinger; Kamal M F Itani; Elie F Berbari; John Segreti; Javad Parvizi; Joan Blanchard; George Allen; Jan A J W Kluytmans; Rodney Donlan; William P Schecter Journal: JAMA Surg Date: 2017-08-01 Impact factor: 14.766
Authors: Helen L Zhang; Judith A Anesi; Keith W Hamilton; Leigh Cressman; Warren B Bilker; Ebbing Lautenbach Journal: Open Forum Infect Dis Date: 2022-07-29 Impact factor: 4.423
Authors: Anna R Wolfson; Christian M Mancini; Aleena Banerji; Xiaoqing Fu; Allison S Bryant; Neelam A Phadke; Erica S Shenoy; Weaam Arman; Yuqing Zhang; Kimberly G Blumenthal Journal: J Allergy Clin Immunol Pract Date: 2020-11-16